| Pharmaceutical Information |
| Drug Name |
Tamsulosin |
| Drug ID |
BADD_D02113 |
| Description |
Tamsulosin is a selective alpha-1A and alpha-1B adrenoceptor antagonist that exerts its greatest effect in the prostate and bladder, where these receptors are most common.[Label] It is indicated for the treatment of signs and symptoms of benign prostatic hypertrophy.[Label] Antagonism of these receptors leads to relaxation of smooth muscle in the prostate and detrusor muscles in the bladder, allowing for better urinary flow.[Label] Other alpha-1 adrenoceptor antagonists developed in the 1980s were less selective and more likely to act on the smooth muscle of blood vessels, resulting in hypotension.[A178351]
Tamsulosin was first approved by the FDA on April 15, 1997.[L6238] |
| Indications and Usage |
Used in the treatment of signs and symptoms of benign prostatic hyperplasia (reduction in urinary obstruction and relief of associated manifestations such as hesitancy, terminal dribbling of urine, interrupted or weak stream...etc.) |
| Marketing Status |
Prescription |
| ATC Code |
G04CA02 |
| DrugBank ID |
DB00706
|
| KEGG ID |
D08560
|
| MeSH ID |
D000077409
|
| PubChem ID |
60147
|
| TTD Drug ID |
D05MBZ
|
| NDC Product Code |
Not Available |
| Synonyms |
Tamsulosin | LY 253352 | LY-253352 | Tamsulosin Hydrochloride | 5-(2-((2-(2-Ethoxyphenoxy)ethyl)amino)propyl)-2-methoxybenzenesulfonamide | Flomax | YM 617 | YM-617 |
|
| Chemical Information |
| Molecular Formula |
C20H28N2O5S |
| CAS Registry Number |
106138-88-9 |
| SMILES |
CCOC1=CC=CC=C1OCCNC(C)CC2=CC(=C(C=C2)OC)S(=O)(=O)N |
| Chemical Structure |
|
|
| ADR Related Proteins Induced by Drug |
| ADR Term |
Protein Name |
UniProt AC |
TTD Target ID |
PMID |
| Not Available | Not Available | Not Available | Not Available | Not Available |
|
| ADRs Induced by Drug |
|
|
